Rezultaty wyszukiwania według autorów

1

Chronic Lung Disease after Premature Birth od Vivek Subbiah

Wydane 2008

Dokumenty pełnotekstowe
Carta

Dodaj do listy ulubionych książek

Zapisane w:
2

The next generation of evidence-based medicine od Vivek Subbiah

Wydane 2023

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
3

Tissue-agnostic cancer therapies: promise, reality, and the path forward od Vivek Subbiah

Wydane 2025

Dokumenty pełnotekstowe
Artigo

Dodaj do listy ulubionych książek

Zapisane w:
4

Challenging Standard-of-Care Paradigms in the Precision Oncology Era od Vivek Subbiah, Razelle Kurzrock

Wydane 2018

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
5

Managing Cancer Care during the COVID-19 Pandemic and Beyond od Omar Alhalabi, Vivek Subbiah

Wydane 2020

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Artigo

Dodaj do listy ulubionych książek

Zapisane w:
6

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis od Vivek Subbiah, Razelle Kurzrock

Wydane 2023

Dokumenty pełnotekstowe
Artigo

Dodaj do listy ulubionych książek

Zapisane w:
7

Tumor-agnostic drug development in dMMR/MSI-H solid tumors od Deepak Bhamidipati, Vivek Subbiah

Wydane 2023

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
8

Clinical development and management of adverse events associated with FGFR inhibitors od Vivek Subbiah, Srđan Verstovšek

Wydane 2023

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
9

Advances in Targeting RET-Dependent Cancers od Vivek Subbiah, Gilbert J. Cote

Wydane 2020

Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
10

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy od Mohamed A. Gouda, Vivek Subbiah

Wydane 2023

Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
11

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors od Mohamed A. Gouda, Vivek Subbiah

Wydane 2023

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
12

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers od Mohamed A. Gouda, Vivek Subbiah

Wydane 2023

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
13

Clinical Development of BRAF plus MEK Inhibitor Combinations od Vivek Subbiah, Christina S. Baik, John M. Kirkwood

Wydane 2020

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
14

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm od Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Wydane 2020

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
15

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives od Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

Wydane 2017

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Artigo

Dodaj do listy ulubionych książek

Zapisane w:
16

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians od Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

Wydane 2020

Dokumenty pełnotekstowe
Editorial

Dodaj do listy ulubionych książek

Zapisane w:
17

State-of-the-Art Strategies for Targeting RET-Dependent Cancers od Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

Wydane 2020

Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
18

The abscopal effect in patients with cancer receiving immunotherapy od Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

Wydane 2023

Dokumenty pełnotekstowe Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
19

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? od Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

Wydane 2025

Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:
20

The emerging role of PI3K inhibitors for solid tumour treatment and beyond od Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Wydane 2023

Dokumenty pełnotekstowe
Revisão

Dodaj do listy ulubionych książek

Zapisane w:

Chronic Lung Disease after Premature Birth od Vivek Subbiah

The next generation of evidence-based medicine od Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward od Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era od Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond od Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> od Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors od Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors od Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers od Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy od Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors od Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers od Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations od Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm od Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives od Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians od Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers od Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy od Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? od Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond od Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Rezultaty - Vivek Subbiah

Chronic Lung Disease after Premature Birth od Vivek Subbiah

The next generation of evidence-based medicine od Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward od Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era od Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond od Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> od Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors od Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors od Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers od Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy od Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors od Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers od Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations od Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm od Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives od Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians od Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers od Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy od Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? od Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond od Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Narzędzie wyszukiwania:

Podobne hasła